We discuss methods of developing consensus in measuring improvement in myositis. We consider selecting candidate variables, reliability and validity, percentage improvement/worsening rules, rules based on CART and logistic regression. We discuss criteria for determining an acceptable rule that include both numerical measures and physician acceptance.
Get full access to this article
View all access options for this article.
References
1.
Breiman L., Friedman JH, Olshen RA, Stone CJClassification and regression trees. Wadsworth International Group, 1984.
2.
Dunham RB1998. Nominal Group Technique: A User's Guide Available on internet at http://instruction.bus.wisc.edu/obdemo/readings/ngt.html or via Google.
3.
FDA Guidance for Industry: Patient Reported Outcomes: Use in Medial Product Development to Support Claims in Approved Labels or Advertising. March 2004 (website: www.fda.gov/cder/regulatory/default.htm )
4.
Felson DT, Anderson JJ, Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R., Paulus H., Tugwell P., Weinblatt M., Widmark R., Williams HJ, Wolfe, F.The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum1993; 36: 729—40.
5.
Felson DT, Anderson JJ, Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Katz LM, Lightfoot, Jr. R., Paulus H., Strand V., Tugwell P., Weinblatt M., Williams HJ, Wolfe F., Kieszak S.American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995 ; 38: 727—35.
6.
Isenberg DA, Allen E., Farewell V., Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C., Pilkington C., Plotz P., Scott D., Vencovsky J., Cooper R., Rider L., Miller F.International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology2004; 43: 49—54.
7.
Miller FW, Rider LG, Chung YL, Cooper R., Danko K., Farewell V., Lundberg I., Morrison C., Oakley L., Oakley I., Pilkington C., Vencovsky J., Vincent K., Scott DL, Isenberg DAProposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology2001; 40: 1262—73.
8.
Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R., Fraser DD, Dalakas M., Plotz PHControlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med1992; 326(21): 1380—4.
Rider LG, Giannini EH, Harris-Love M., Joe G., Isenberg D., Pilkington C., Lachenbruch PA, Miller FWDefining clinical improvement in adult and juvenile myositis. J Rheumatol2003; 30: 603—17.
11.
Rider LGOutcome assessment in the adult and juvenile idiopathic inflammatory myopathies . Rheum Dis Clin North Am2002; 28: 935—77.
12.
Rider LG, Giannini EH, Brunner HI, Ruperto N., James-Newton L., Reed AM, Lachenbruch PA, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS) 6.International Consensus on Outcome Measures for Patients with Idiopathic Inflammatory Myopathies. Preliminary Definitions of Improvement for Adult and Juvenile Myositis. Arthritis Rheum2004; 50: 2281—90.
